Edward P. Monaghan

Kadmus Pharmaceuticals, Inc. manufactures and sells biopharmaceutical products. It develops and commercializes proprietary molecules targeting critical pathways contributing to pain, disorders of the nervous system, and other unmet medical needs. The firm also performs formulation, pre-clinical development and also oversees the manufacturing, preclinical toxicology, and clinical development of candidate drugs via a key vendor network. Kadmus Pharmaceuticals was founded in 1998 and is headquartered in Irvine, CA.

CoCensys, Inc. discovers and develops drugs to treat neurological and psychiatric disorders. The company's product development programs focus on two novel and proprietary classes of compounds: Epalons, to treat epilepsy, migraine, anxiety and sleep disorders and Excitatory Amino Acid (EAA) receptor antagonists, to treat stroke, head trauma, epilepsy and Parkinson's disease. The company was founded in 1989 and is located in Irvine, CA.

Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA.

Thesan Pharmaceuticals, Inc. provides novel therapeutics for disorders of the skin. The company focuses on the discovery and development of new chemical entities that provide improved treatment options to patients. Thesan Pharmaceuticals was founded in 2011 by Edward P. Monaghan and is headquartered in Carlsbad, CA.

EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA.

Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin.